Tourmaline Bio, Inc. (TRML)
(Real Time Quote from BATS)
$15.81 USD
+0.26 (1.67%)
Updated May 9, 2024 02:50 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRML 15.81 +0.26(1.67%)
Will TRML be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going
Here's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price Strength
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'
Other News for TRML
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
3 Best Stocks to Buy Now, 3/26/2024, According to Top Analysts
Truist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)
Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish